Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Katsuhiko Takabayashi, Fumihiko Ando & Takahiro Suzuki. (2019) Comparing the effectiveness of biological disease-modifying antirheumatic drugs using real-world data. Modern Rheumatology 29:1, pages 87-97.
Read now
Read now
Walid Fakhouri, Pedro Lopez-Romero, Silvia Antonelli, Serena Losi, Veronica Rogai, Stefano Buda, Diego Sangiorgi, Valentina Perrone & Luca Degli Esposti. (2018) Treatment patterns, health care resource utilization and costs of rheumatoid arthritis patients in Italy: findings from a retrospective administrative database analysis. Open Access Rheumatology: Research and Reviews 10, pages 103-111.
Read now
Read now
Luca Degli Esposti, Ennio Giulio Favalli, Diego Sangiorgi, Roberta Di Turi, Giuseppina Farina, Marco Gambera & Roberto Ravasio. (2017) Persistence, switch rates, drug consumption and costs of biological treatment of rheumatoid arthritis: an observational study in Italy. ClinicoEconomics and Outcomes Research 9, pages 9-17.
Read now
Read now
Ning Wu, Sharvari Bhurke, Neel Shah & David J Harrison. (2015) Application of a validated algorithm to estimate the effectiveness and cost of biologics for rheumatoid arthritis in the US pharmacy benefit manager context. ClinicoEconomics and Outcomes Research 7, pages 257-266.
Read now
Read now
Vasilis Fragoulakis, Elli Vitsou, Ana Cristina Hernandez & Nikolaos Maniadakis. (2015) Economic evaluation of anti-TNF agents for patients with rheumatoid arthritis in Greece. ClinicoEconomics and Outcomes Research 7, pages 85-93.
Read now
Read now
Diego Sangiorgi, Maurizio Benucci, Carmela Nappi, Valentina Perrone, Stefano Buda & Luca Degli Esposti. (2015) Drug usage analysis and health care resources consumption in naïve patients with rheumatoid arthritis. Biologics: Targets and Therapy 9, pages 119-127.
Read now
Read now
Machaon Bonafede, Barbara H. Johnson, Nicole Princic, Neel Shah & David J. Harrison. (2015) Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis. Journal of Medical Economics 18:5, pages 376-389.
Read now
Read now
Joaquín Borrás-Blasco & Andres Navarro Ruiz. (2015) Dose modification of anti-TNF in rheumatoid arthritis and estimated economical impact: a review of observational studies. Expert Review of Pharmacoeconomics & Outcomes Research 15:1, pages 71-79.
Read now
Read now
Machaon Bonafede, George J Joseph, Neel Shah, Nicole Princic & David J Harrison. (2014) Cost of tumor necrosis factor blockers per patient with rheumatoid arthritis in a multistate Medicaid population. ClinicoEconomics and Outcomes Research 6, pages 381-388.
Read now
Read now
Amie T. Joyce, Shravanthi R. Gandra, Kathleen M. Fox, Timothy W. Smith & Michael W. Pill. (2014) National and regional dose escalation and cost of tumor necrosis factor blocker therapy in biologic-naïve rheumatoid arthritis patients in US health plans. Journal of Medical Economics 17:1, pages 1-10.
Read now
Read now
Machaon Bonafede, George J. Joseph, Nicole Princic & David J. Harrison. (2013) Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis. Journal of Medical Economics 16:9, pages 1120-1128.
Read now
Read now
Maxine D. Fisher, Crystal Watson, Kathleen M. Fox, Yen-Wen Chen & Shravanthi R. Gandra. (2013) Dosing patterns of three tumor necrosis factor blockers among patients with rheumatoid arthritis in a large United States managed care population. Current Medical Research and Opinion 29:5, pages 561-568.
Read now
Read now
Articles from other publishers (11)
Min-Young Lee, Ju-Young Shin, Sun-Young Park, Donguk Kim, Hoon-Suk Cha & Eui-Kyung Lee. (2018) Persistence of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: An analysis of the South Korean National Health Insurance Database. Seminars in Arthritis and Rheumatism 47:4, pages 485-491.
Crossref
Crossref
Anagha Nadkarni, Donna McMorrow, Chad Patel, Robert Fowler & David Smith. (2017) Incidence of dose escalation and impact on biologic costs among patients with rheumatoid arthritis treated with three intravenous agents. Journal of Comparative Effectiveness Research 6:8, pages 671-682.
Crossref
Crossref
Jordana Schmier, Kristine Ogden, Nancy Nickman, Michael T. Halpern, Mary Cifaldi, Arijit Ganguli, Yanjun Bao & Vishvas Garg. (2017) Costs of Providing Infusion Therapy for Rheumatoid Arthritis in a Hospital-based Infusion Center Setting. Clinical Therapeutics 39:8, pages 1600-1617.
Crossref
Crossref
Xuefeng Wang, Li Li, Jun Wang, Liyang Dong, Yang Shu, Yong Liang, Liang Shi, Chengcheng Xu, Yuepeng Zhou, Yi Wang, Deyu Chen & Chaoming Mao. (2017)
Inhibition of cytokine response to TLR stimulation and alleviation of collagen-induced arthritis in mice by
Schistosoma japonicum
peptide SJMHE1
. Journal of Cellular and Molecular Medicine 21:3, pages 475-486.
Crossref
Crossref
Paolo Faccendini, Enrica Cantillo, Caterina Fanizza & Maria Grazia Celeste. (2017) Analisi di Farmacoutilizzazione dei Trattamenti Biologici Nelle Malattie Infiammatorie Immunomediate Croniche: I Risultati di Uno Studio Osservazionale Retrospettivo Condotto in un Centro Ospedaliero del Centro Italia. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish 4:1, pages grhta.5000271.
Crossref
Crossref
James Harnett, Robert Gerber, David Gruben, Andrew S. KoenigConnie Chen. (2016) Evaluation of Real-World Experience with Tofacitinib Compared with Adalimumab, Etanercept, and Abatacept in RA Patients with 1 Previous Biologic DMARD: Data from a U.S. Administrative Claims Database. Journal of Managed Care & Specialty Pharmacy 22:12, pages 1457-1471.
Crossref
Crossref
Tao Gu, Neel Shah, Gaurav Deshpande, Derek H. Tang & Debra F. Eisenberg. (2016) Comparing Biologic Cost Per Treated Patient Across Indications Among Adult US Managed Care Patients: A Retrospective Cohort Study. Drugs - Real World Outcomes 3:4, pages 369-381.
Crossref
Crossref
James Harnett, Jeffrey R. Curtis, Robert Gerber, David Gruben & Andrew Koenig. (2016) Initial Experience With Tofacitinib in Clinical Practice: Treatment Patterns and Costs of Tofacitinib Administered as Monotherapy or in Combination With Conventional Synthetic DMARDs in 2 US Health Care Claims Databases. Clinical Therapeutics 38:6, pages 1451-1463.
Crossref
Crossref
Rafael Ferriols-Lisart & Francisco Ferriols-Lisart. (2015) Dose modifications of anti-TNF drugs in rheumatoid arthritis patients under real-world settings: a systematic review. Rheumatology International 35:7, pages 1193-1210.
Crossref
Crossref
Grant W. Cannon, Scott L. DuVall, Candace L. Haroldsen, Liron Caplan, Jeffrey R. Curtis, Kaleb Michaud, Ted R. Mikuls, Andreas Reimold, David H. Collier, David J. Harrison, George J. Joseph & Brian C. Sauer. (2014) Persistence and Dose Escalation of Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis. The Journal of Rheumatology 41:10, pages 1935-1943.
Crossref
Crossref
Steven W. Blume, Kathleen M. Fox, George Joseph, Chien-Chia Chuang, Jessy Thomas & Shravanthi R. Gandra. (2013) Tumor Necrosis Factor-Blocker Dose Escalation in Rheumatoid Arthritis Patients in a Pharmacy Benefit Management Setting. Advances in Therapy 30:5, pages 517-527.
Crossref
Crossref